{
CRISPR Therapeutics AG

Companies

}
001122334455554433221100
001122334455554433221100
Symbol CRSP
Name CRISPR Therapeutics AG
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country Switzerland
State
City Zug
Zipcode 6300
Website http://www.crisprtx.com
Track all markets on TradingView

healthcare innovation portfolio targets advancements in pharmaceuticals and medical technologies

The convergence of science and technology is transforming healthcare, with Syfe's Healthcare Innovation portfolio offering diversified investment across genomics, biotechnology, pharmaceuticals, healthcare services, and medical devices. This portfolio includes six carefully selected ETFs, providing exposure to leading companies and innovations in the sector, while managing risks associated with long-term healthcare investments. With no minimum investment and low fees, it aims to capitalize on the future of healthcare advancements.
Connect
Masimo Corporation Vertex Pharmaceuticals Incorporated Abbott Laboratories GE HealthCare Technologies Inc. AtriCure, Inc. Regeneron Pharmaceuticals, Inc. Intuitive Surgical, Inc. CRISPR Therapeutics AG Veeva Systems Inc. Johnson & Johnson Cigna Integra LifeSciences Holdings Corporation CVS Health Corporation Stryker Corporation UnitedHealth Group Incorporated Amgen Inc. Penumbra, Inc. Alphatec Holdings, Inc. UCB SA Boston Scientific Corporation Eli Lilly and Company USA BEL Beigene Revolution Medicines Gilead Sciences Exelixis Incyte Show more
Finance & Economy, Market Report
02:52 13.11.2024

ipr001 begins first human trial as global crispr market expands rapidly

SNIPR BIOME ApS has initiated the first human clinical trial for SNIPR001, targeting E. coli colonization in healthy volunteers, set to begin in the first half of 2022. The global CRISPR technology market is projected to grow significantly, with North America leading in market share, driven by advancements in biomedical applications and increasing research activities.
Spherical Insights
United States Dollar Integrated DNA Technologies Inc. Mirus Bio LLC Sangamo Therapeutics, Inc. CRISPR Therapeutics AG Genscript Abbott Laboratories Merck & Co., Inc. NEW England Biolabs Inc. Thermo Fisher Scientific Inc. Lonza Group AG Takara Bio Inc. ABio-Rad Laboratories Inc USA DEU MEX ITA ARG AUS ZAF IND RUS JPN KOR GBR BRA CAN ARE ESP CHN Show more
Healthcare, Market Report
20:26 28.10.2024

emerging sectors driving growth in technology healthcare and green energy by 2025

The technology, healthcare, and green energy sectors are poised for significant growth by 2025, driven by advancements in AI, 5G, and biotechnology, alongside a global shift towards renewable energy. Telemedicine and digital health innovations are transforming healthcare, while the push for carbon neutrality accelerates investments in solar, wind, and hydrogen energy. These sectors present attractive opportunities for investors amid ongoing economic transformations.
ideal-investisseur.fr
United States Dollar Euro Teladoc Health, Inc. Neoen S.A. NextEra Energy, Inc. Engie SA Tesla, Inc. Rivian Automotive, Inc. Microsoft Corporation CRISPR Therapeutics AG Tesla Energy Alphabet (Google) Apple Inc. Fitbit Inc. Varta AG Plug Power Inc. Iberdrola, S.A. Moderna, Inc. NVIDIA Corporation Intel Corporation L'Air Liquide S.A. Amwell Associates LLC TSMC (Taiwan Semiconductor Manufacturing Company) Siemens Energy AG Schneider Electric S.E. Medtronic Defined Contribution Plan Master Trust TWN FRA USA DEU Joe Biden Ursula von der Leyen Angela Merkel Emmanuel Macron Elon Musk Show more
Finance & Economy, Market Report
09:00 25.10.2024

editas seeks partner for gene editing therapy amid strategic shift

Editas Medicine is seeking a partner or considering out-licensing its lead gene editing therapy, reni-cel, aimed at treating sickle cell disease and beta thalassemia. This shift comes as the company pivots from previous strategies and aims to reduce spending while advancing its research. Despite promising preclinical data, Editas faces challenges in bringing reni-cel to market, prompting a focus on in vivo gene editing for future treatments.
BioPharma Dive
United States Dollar Moelis & Company Vertex Pharmaceuticals Incorporated Genevant Sciences CRISPR Therapeutics AG Editas Medicine, Inc. USA Gilmore O’Neill Dae Gon Ha Show more
Healthcare, News Article
17:15 22.10.2024
Trending
Subcategory
Corporate News Industry Trends Cryptocurrency Trends Venture Capital Investments Emerging Startups Funding Rounds & Investments Fintech Startups AI Innovations Startups & Entrepreneurship Crypto Adoption and Integration AI Applications Retail and Consumer Goods Crypto Policies and Governance Product Launches Workplace Trends Economic Indicators Central Banks and Digital Currencies IPOs of Tech Companies Market Analysis and Predictions Banking Regulations
Countries:
USA IND CHN JPN SGP ARE DEU SAU GBR IDN ISR HKG TWN EGY POL KOR AUS VNM RUS OMN
Companies:
Apple Inc. Nvidia Corporation DEUTSCHE BANK AG EVOLUTION JAPAN Securities Co. Ltd. Alphabet Inc. Marvell Technology Inc. Playtika Holding Corp. Colugo Systems Ltd. Gemini Trust Company LLC Circle Internet Financial Inc. Citigroup Inc. Bank of America Corporation Sony Corporation Zero Networks Ltd. Ecom Express Ltd. Minebea Mitsumi Inc. VOLKSWAGEN AG
Currencies:
United States Dollar Indian Rupee Chinese Yuan New Taiwan Dollar
People:
Elon Musk Donald Trump Joe Biden Teo Chee Hean Cristiano Ventricelli Scott Bessent Matt Hougan Howard Lutnick Sabih Behzad Andrew Bosworth Mary Meeker Suresh Ts Vijay Kuppa Pierre Chen Shigeru Ishiba Shinichi Uchida Vivek Gupta Sean Kelly Terry Gou Saurav Kumar

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.